AAVAnc80-antiVEGF Gene Therapy (Akouos)

N/A

Report date: 2025/12/08 20:00:58

Base Information

Drug NameAAVAnc80-antiVEGF Gene Therapy (Akouos)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVAnc80 vector
Mechanisms of ActionAnti-Vascular endothelial growth factor
TargetsVascular endothelial growth factor
Therapy Area/IndicationsNeuroma, Acoustic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAkouos Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyAkouos Inc
Inactive CompaniesN/A
Active IndicationsNeuroma, Acoustic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A